| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Departments of Medicine, Genetics and Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 [G. S. W., T. F. B., W. S. E-D.], and Kimmel Cancer Institute, BLSB, Thomas Jefferson University, Philadelphia, PA 19107 [Y. Z., E. S. A.]
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors are members of the tumor necrosis factor superfamily. TRAIL selectively kills cancer cells but not normal cells. We report here the cloning of the mouse homologue of the TRAIL receptor KILLER/DR5 (MK). The cDNA of MK is 1146 bp in length and encodes a protein of 381 amino acids. MK contains an extracellular cysteine-rich domain, a transmembrane domain, and a cytoplasmic death-domain characteristic of Fas, tumor necrosis factor, and human TRAIL receptors. MK is highly homologous and binds TRAIL with similar affinity as human DR4 and KILLER/DR5. MK induces apoptosis in mouse and human cells and inhibits colony growth of NIH3T3 cells. Expression of MK is p53-dependent and up-regulated by tumor suppressor p53 and by DNA damaging agents in mouse cells undergoing apoptosis. This is the first report describing a mouse TRAIL receptor gene and also demonstrating that the p53-dependent regulation of KILLER/DR5-mediated apoptosis is conserved between human and mouse.
This article has been cited by other articles:
|
|
 |
|
  E.-S. Sung, K.-J. Park, S.-H. Lee, Y.-S. Jang, S.-K. Park, Y.-H. Park, W.-J. Kwag, M.-H. Kwon, and Y.-S. Kim A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes Mol. Cancer Ther., August 1, 2009; 8(8): 2276 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Frew, R. K. Lindemann, B. P. Martin, C. J. P. Clarke, J. Sharkey, D. A. Anthony, K.-M. Banks, N. M. Haynes, P. Gangatirkar, K. Stanley, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist PNAS, August 12, 2008; 105(32): 11317 - 11322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Sacks and M. J. Bevan TRAIL Deficiency Does Not Rescue Impaired CD8+ T Cell Memory Generated in the Absence of CD4+ T Cell Help J. Immunol., April 1, 2008; 180(7): 4570 - 4576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Rus, V. Nguyen, R. Puliaev, I. Puliaeva, V. Zernetkina, I. Luzina, J. C. Papadimitriou, and C. S. Via T Cell TRAIL Promotes Murine Lupus by Sustaining Effector CD4 Th Cell Numbers and by Inhibiting CD8 CTL Activity J. Immunol., March 15, 2007; 178(6): 3962 - 3972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Xu, J.-Y. Zhou, M. A. Tainsky, and G. S. Wu Evidence that Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Induction by 5-Aza-2'-Deoxycytidine Sensitizes Human Breast Cancer Cells to Adriamycin Cancer Res., February 1, 2007; 67(3): 1203 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, J.-Y. Zhou, and G. S. Wu Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Is Required for Tumor Necrosis Factor {alpha}-Mediated Sensitization of Human Breast Cancer Cells to Chemotherapy. Cancer Res., October 15, 2006; 66(20): 10092 - 10099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Murata, M. Tsuboi, K. Hikita, and N. Kaneda Protective Effects of Neurotrophic Factors on Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Apoptosis of Murine Adrenal Chromaffin Cell Line tsAM5D J. Biol. Chem., August 11, 2006; 281(32): 22503 - 22516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ishikawa, M. Nakazawa, M. Yoshinari, and M. Minami Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Immune Response to Influenza Virus Infection in Mice J. Virol., June 15, 2005; 79(12): 7658 - 7663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Finnberg, J. J. Gruber, P. Fei, D. Rudolph, A. Bric, S.-H. Kim, T. F. Burns, H. Ajuha, R. Page, G. S. Wu, et al. DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis Mol. Cell. Biol., March 1, 2005; 25(5): 2000 - 2013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-G. Jin, A. Kurakin, N. Benhaga, K. Abe, M. Mohseni, F. Sandra, K. Song, B. K. Kay, and R. Khosravi-Far Fas-associated Protein with Death Domain (FADD)-independent Recruitment of c-FLIPL to Death Receptor 5 J. Biol. Chem., December 31, 2004; 279(53): 55594 - 55601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Zheng, J. Jiang, H. Shen, and Y. H. Chen Reduced Apoptosis and Ameliorated Listeriosis in TRAIL-Null Mice J. Immunol., November 1, 2004; 173(9): 5652 - 5658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Riley, J. M. Heeley, A. H. Wyman, E. L. Schlichting, and K. H. Moley TRAIL and KILLER Are Expressed and Induce Apoptosis in the Murine Preimplantation Embryo Biol Reprod, September 1, 2004; 71(3): 871 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Sax and W. S. El-Deiry Identification and Characterization of the Cytoplasmic Protein TRAF4 as a p53-regulated Proapoptotic Gene J. Biol. Chem., September 19, 2003; 278(38): 36435 - 36444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-E. Lamhamedi-Cherradi, S. Zheng, R. M. Tisch, and Y. H. Chen Critical Roles of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Type 1 Diabetes Diabetes, September 1, 2003; 52(9): 2274 - 2278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-S. Mi, D. Ly, S.-E. Lamhamedi-Cherradi, K. V. Salojin, L. Zhou, M. Grattan, C. Meagher, P. Zucker, Y. H. Chen, J. Nagle, et al. Blockade of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Exacerbates Type 1 Diabetes in NOD Mice Diabetes, August 1, 2003; 52(8): 1967 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schneider, D. Olson, A. Tardivel, B. Browning, A. Lugovskoy, D. Gong, M. Dobles, S. Hertig, K. Hofmann, H. Van Vlijmen, et al. Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) J. Biol. Chem., February 7, 2003; 278(7): 5444 - 5454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-o. Lee, J. M. Herndon, R. Barreiro, T. S. Griffith, and T. A. Ferguson TRAIL: A Mechanism of Tumor Surveillance in an Immune Privileged Site J. Immunol., November 1, 2002; 169(9): 4739 - 4744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Werner, E. de Vries, S. W. G. Tait, I. Bontjer, and J. Borst TRAIL Receptor and CD95 Signal to Mitochondria via FADD, Caspase-8/10, Bid, and Bax but Differentially Regulate Events Downstream from Truncated Bid J. Biol. Chem., October 18, 2002; 277(43): 40760 - 40767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice J. Immunol., February 1, 2002; 168(3): 1356 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takeda, M. J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita, and K. Okumura Critical Role for Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development J. Exp. Med., January 14, 2002; 195(2): 161 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hilliard, A. Wilmen, C. Seidel, T.-S. T. Liu, R. Goke, and Y. Chen Roles of TNF-Related Apoptosis-Inducing Ligand in Experimental Autoimmune Encephalomyelitis J. Immunol., January 15, 2001; 166(2): 1314 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Y. Sun, P. Yue, W. K. Hong, and R. Lotan Augmentation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by the Synthetic Retinoid 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene Carboxylic Acid (CD437) through Up-Regulation of TRAIL Receptors in Human Lung Cancer Cells Cancer Res., December 1, 2000; 60(24): 7149 - 7155. [Abstract] [Full Text]
|
|
|
|
|
|
K. Song, Y. Chen, R. Goke, A. Wilmen, C. Seidel, A. Goke, B. Hilliard, and Y. Chen Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression J. Exp. Med., April 3, 2000; 191(7): 1095 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Kuang, G. E. Diehl, J. Zhang, and A. Winoto FADD Is Required for DR4- and DR5-mediated Apoptosis. LACK OF TRAIL-INDUCED APOPTOSIS IN FADD-DEFICIENT MOUSE EMBRYONIC FIBROBLASTS J. Biol. Chem., August 11, 2000; 275(33): 25065 - 25068. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
